Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology

Key Points. Antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients with is markedly impaired and affected by disease activity and treatment.In patie

Read the full article here

Related Articles